Mission

The 10,000 Brains Project is a nonprofit initiative dedicated to advancing targeted therapies for the millions of people affected by neurodegenerative diseases worldwide. By working across neurodegenerative diseases and harnessing the full potential of innovative tools and technologies, we aim to accelerate breakthroughs in  earlier detection and more personalized care.

Vision

We envision a future where innovative technologies—such as artificial intelligence (AI) and big data analytics— unlock new insights across neurodegenerative disorders, enabling earlier detection and more personalized treatment for all patients.

Origin Story

The 10,000 Brains Project was created in 2023 by Kathy Harvard, Michael Maynard, and Everett Cook, three passionate, longtime patient advocates whose family and friends had been affected by various neurodegenerative diseases. What started as an effort to raise greater awareness about brain diseases quickly evolved into a plan for real action. Seeking a greater sense of urgency and more progress toward the cures patients need, they founded The 10,000 Brains Project to drive change in the way research is done.

Patrick Brannelly has a long track as a leader and change agent in neuroscience. He had previously worked with the founders on other initiatives over the years and was an informal advisor to them as they incubated The 10,000 Brains Project. He joined them as the organization’s founding CEO in 2023. Pat is passionate about bringing neuroscience research into the digital age, creating the conditions for breakthroughs that more traditional approaches could never achieve.

10,000 Brains is proof that when personal experience meets visionary leadership, real change is possible. And this movement isn’t limited to scientists or advocates— there is space for everyone to play a role in reshaping the future of neurodegenerative disease research.

Staff

Patrick Brannelly

CEO and Board Member

Mukta Phatak

Vice President of Data Strategy

Board of Directors

Everett Cook

Co-Chair of the Board

Kathy Harvard

Board Member

David Kemp

Board Member and Treasurer

Oliver Kennan

Board Member and Secretary

Michael Maynard

Co-Chair of the Board

Ralph Terkowitz

Board Member

Advisors

Steve Altschuler, PhD

Professor of Pharmaceutical Chemistry

The University of California, San Francisco

John Crary, MD, PhD

Professor of Pathology and Neuroscience

The Icahn School of Medicine at Mount Sinai, NY

Kristophe Diaz, PhD

Executive Director

Chief Science Officer

CurePSP

Thomas Fuchs, DrSc

Chief AI Officer

Eli Lilly and Company

Frances Jensen, MD

Professor of Neurology

Chairman of Neurology

The Perelman School of Medicine at

the University of Pennsylvania

Ann McKee, MD

Professor of Neurology

Pathology Director

Boston University CTE Center

Eric Nestler, MD, PhD

Director, Friedman Brain Institute

Chief Scientific Officer

The Icahn School of Medicine

at Mount Sinai, NY

Bill Seeley, MD

Professor of Neurology and Pathology

The Memory and Aging Center

The University of California, San Francisco

Genevieve Stein-O’Brien, MHS, PhD

Assistant Professor of Neuroscience at the Brain Science Institute

Associate Director of the JHU Single-Cell Training and Analysis Center

Johns Hopkins University

Sally Temple, PhD

Scientific Director

Neural Stem Cell Institute University at Albany

State University of New York

Lani Wu, PhD

Professor of Pharmaceutical Chemistry

The University of California, San Francisco